Abstract:Abstract Cancer immunotherapy is an effective treatment against individuals with late-stage cancer forms. The PD-1/PD-LI axis is a main therapeutic target used in clinical settings, but only 15-20% of cancer patients are responsive. Thus, there is an urgent unmet need to identify other immuno-therapeutic targets to overcome this limitation. Butyrophilin (BTN) belongs to the B7 family, peripheral membrane proteins containing an immunoglobulin domain found in PD-L1 and CTLA4. Among the BTN family, BTN2A2 and BTN3A1 are shown as alternative co-inhibitory or co-stimulatory cancer immune checkpoint(s) in the effector T cell compartment. However, the immune-modulatory roles of BTN1A1 are largely unknown, especially in vivo. Here, we report the immune-modulatory role of BTN1A1 in T cell proliferation and activation in vitro and in vivo. We have found that BTN1A1 inhibits the proliferation of T cells that are activated by anti-CD3 and anti-CD28 antibodies in vitro. The overexpression of BTN1A1 in PC3 cells also inhibits T cell-mediated cancer cell killing. BTN1A1-overexpressing B16-Ova melanoma cancer cell lines also accelerate tumor growth compared to B16-Ova wild type in a syngeneic mouse model. The effect of BTN1A1 was fully attenuated in an immune-compromised SCID mouse. BTN1A1-deficient MC38 colorectal cancer cell lines also grew significantly slower than wild-type MC38 cell lines when they were inoculated subcutaneously into a syngeneic mouse model. This result strongly supports BTN1A1's role in immune evasion. BTN1A1 is expressed on immune cells. These cells include macrophages, B cells or activated CD8 T cells. We found that BTN1A1 is expressed in human tumors, with an expression that was mutually exclusive to PD-L1. We have developed the monoclonal antibody (STC810) against the human BTN1A1. STC810 has anti-tumor activity in a human immune environment in vitro and ex vivo. Since STC810 has no cross-reactivity with mouse BTN1A1 proteins, we generated mouse surrogate antibodies to study the effects of blocking BTN1A1 in vivo in mice tumor models. The anti-BTN1A1 surrogate antibody not only exhibits a single agent but has a synergistic effect in combination with the anti-PD-L1 antibody. Overall, using mouse models, genetic ablation, and antibody tests ex vivo we demonstrate that BTN1A1 is a bona fide immune checkpoint inhibitor. Late-stage preclinical studies of humanized STC810 are underway. The Phase I clinical trial is set to start in late 2021. Citation Format: Ezra M. Chung, Yong-Sik Bong, Young-Seung Kim, Andrew Park, Young-Ok You, Amrish Sharma, Steven H. Lin, Young-Joon Lee, Hyunjin Jung, Stephen S. Yoo. BTN1A1: a novel immune checkpoint for cancer immunotherapy beyond the PD-1/PD-L1 axis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1643.

BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

MNK2 Governs the Macrophage Antiinflammatory Phenotype.

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages

Reprogramming of breast tumor-associated macrophages with modulation of arginine metabolism

TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype

Abstract 1643: BTN1A1: a novel immune checkpoint for cancer immunotherapy beyond the PD-1/PD-L1 axis

A subpopulation of CD146 + macrophages enhances antitumor immunity by activating the NLRP3 inflammasome

TBK1-Zyxin signaling controls tumor-associated macrophage recruitment to mitigate antitumor immunity

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.

Tumor Cell SPTBN1 Inhibits M2 Polarization of Macrophages by Suppressing CXCL1 Expression.

Wnt signaling in the phenotype and function of tumor-associated macrophages.

Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

Critical role of CD206+ macrophages in promoting a cDC1-NK-CD8 T cell anti-tumor immune axis

Targeting BTN2A1 enhances Vγ9Vδ2 T-cell effector functions and triggers tumor cell pyroptosis

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer

Mechanistic studies of tumor-associated macrophage immunotherapy

Butyrophilin 2A2 promotes T cell immunoregulation by enhancing CD45 phosphatase activity within the immune synapse